Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer involved in NIH scandal

Executive Summary

A House Energy & Commerce Committee investigation finds that the National Institute for Mental Health Geriatric Psychiatry Branch Chief Trey Sunderland improperly shared spinal fluid and plasma samples with Pfizer. He received $285,000 for consulting work related to the samples. However, the committee finds "no evidence that Pfizer had any knowledge relating to the questionable conduct of Dr. Sunderland in connection with the [relevant Material Transfer Agreement] and the subsequent shipments of samples"...

You may also be interested in...



HHS OIG Conflict-Of-Interest Investigations To Focus On NIH Rather Than FDA

The HHS Office of Inspector General will focus its conflict-of-interest enforcement efforts on the National Institutes of Health in 2007, causing it to postpone pending studies of FDA

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel